Amikacin, Peak, Serum
Use
Monitoring adequacy of serum concentration during amikacin therapy. Amikacin is an aminoglycoside used to treat severe blood infections caused by susceptible strains of gram-negative bacteria. The drug works by irreversibly binding to bacterial ribosomes to inhibit protein synthesis. Monitoring of peak serum concentrations is crucial as it ensures effective dosing while minimizing toxicity risks associated with the drug.
Special Instructions
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
Limitations
Serum half-lives of amikacin in patients with normal renal function are generally 2 to 3 hours, but can be prolonged in those with impaired renal function, leading to accumulation. Toxic effects may include dizziness, vertigo, and ataxia, as well as auditory and nephrotoxicity. Monitoring serum concentrations is necessary to prevent these toxicities and ensure therapeutic efficacy.
New York Approved
Methodology
Immunoassay (Other)
Biomarkers
LOINC Codes
- 3319-1
- 3319-1
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.25 mL
Container
Plastic vial; Preferred: Serum gel; Acceptable: Red top
Collection Instructions
Serum gel tubes should be centrifuged within 2 hours of collection. Red top tubes should be centrifuged, and the serum aliquoted into a plastic vial within 2 hours of collection.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 14 days |
| Frozen | 28 days |